Surface Oncology is an immuno-oncology company focused on using its knowledge of the biological pathways crucial to the immunosuppressive tumor microenvironment (TME) for the development of cancer therapies. NZV930 and SRF617 are antibodies inhibiting cluster of differentiation (CD) 73 and CD39, respectively, and illustrate how Co.'s knowledge of TME biology can be utilized across programs. SRF388 is an antibody targeting interleukin 27, an immunosuppressive cytokine, or protein that is overexpressed in certain cancers, including hepatocellular, lung and renal cell carcinoma. GSK4381562 is an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells. We show 24 historical shares outstanding datapoints in our coverage of SURF's shares outstanding history.
Understanding the changing numbers of SURF shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SURF versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SURF by allowing them to research SURF shares outstanding history
as well as any other stock in our coverage universe. |
Free SURF Email Alerts:
Video: Shares Outstanding Importance
